SciClone Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 80   

Articles published

SCLN 8.63 -0.05 (-0.58%)
price chart
Stock to Focus SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)
[Market Wired] SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) (Trend Analysis) announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the Aegis Capital Corp.
Update: SciClone Pharmaceuticals Exceeds Earnings Estimates For Q3 (SCLN)
SciClone Pharmaceuticals (NASDAQ:SCLN) exceeded earnings estimates for Q3 by 3 cents per share, or 25% on a diluted EPS basis.
SciClone Pharmaceuticals Stock Rating Lowered by BWS Financial (SCLN)  Ticker Report
BWS Financial Downgrades SciClone Pharmaceuticals to Hold (SCLN)  Mideast Time
Related articles »  
Stock Insights on SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)
[Equities.com] SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) hit a new 52-week high, reaching a peak of $8.44 after opening at $8.03 and closing at $8.24 for a move of 1.73%.
Related articles »  
SciClone Pharmaceuticals to Report Financial Results for the Third Quarter ...
FOSTER CITY, CA, Oct 30, 2014 (Marketwired via COMTEX) -- SciClone Pharmaceuticals, Inc. SCLN, -2.66% today announced that it plans to report financial results for the third quarter 2014 on Monday, November 10, 2014.
SciClone Pharmaceuticals Inc.: SciClone Pharmaceuticals to Report Financial ...  The Wall Street Transcript
Related articles »  
Commit To Buy SciClone Pharmaceuticals At $7.50, Earn 15.5% Annualized ...
Investors eyeing a purchase of SciClone Pharmaceuticals, Inc. (Symbol: SCLN) shares, but tentative about paying the going market price of $8.30/share, might benefit from considering selling puts among the alternative strategies at their disposal.
SciClone Pharmaceuticals, Inc. (SCLN) Releases FY14 Earnings Guidance  sleekmoney
Related articles »  
4 stocks display high gross margins: SciClone Pharmaceuticals, Inc. (SCLN ...
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) has return on equity ratio of 14.20%. The company has $440.68 million in market worth.
Related articles »  
SciClone Pharmaceuticals, Inc. (SCLN): SciClone Pharmaceuticals ...
Good day, ladies and gentlemen, and welcome to the Second Quarter 2013 SciClone Pharmaceuticals Inc. Earnings Conference Call.
Related articles »  
SciClone Pharmaceuticals: Promising Biotech With China Exposure
SciClone Pharmaceuticals (NASDAQ:SCLN) is a $271.89 million small-cap biotech company based in the United States, but primarily focused on selling drugs in China.
Related articles »  
SciClone Pharmaceuticals, Inc. (SCLN): SciClone Pharmaceuticals rises ...
Q3 Zadaxin sales: $25M. That's +15% sequentially, but -20% Y/Y. CEO Friedhelm Blobel notes that while SCLN "expects to see continued growth through the remainder of the year, [the company] expects the rate of growth to continue to be affected by ...
Related articles »  
SciClone Pharmaceuticals: A Promising Biotech Stock
SciClone CEO Friedhelm Blobel announced in the Q3 2012 conference call that demand for Chinese pharmaceutical products is expected to grow at a rate of 15%, which SciClone will benefit from. The company has a substantial international business and it ...
Related articles »